Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
NCT06807437Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- May 2025
- Primary completion
- Nov 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic fistula (POPF) comparing Arm I (lanreotide, distal pancreatectomy) with Arm II (saline placebo, distal pancreatectomy) (2 arms). Primary endpoint: Incidence of postoperative pancreatic fistula at 60 days. Started May 2025; status: recruiting.
02
Drugs
lanreotide
03
Conditions
pancreatic fistula (POPF)
Beyond the preview
Go deeper on NCT06807437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06807437.